Summary
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
History
Innovent Biologics was founded in 2011 by a team of dedicated industry professionals. Since then, the company has grown to become one of the leading biopharmaceutical companies in China, focusing on the research and development of innovative biologics. Our products have been approved by the Chinese Regulatory Authority and are currently marketed in China and abroad.
Mission
Innovent Biologics is committed to providing innovative and high quality medicines to treat cancer, autoimmune diseases, and other major diseases throughout China and globally.
Vision
Our vision is to become the world’s leading biologic company and provide effective treatments for cancer, autoimmune diseases, and other major diseases.
Key Team
Mr. Min Liu (Chief Commercial Officer)
Mr. Dongming Wang (Sr. VP of Quality)
Mr. Blake Salisbury (Sr. VP of Bus. Devel.)
Ms. Yanju Wang (Joint Company Sec.)
Ms. Lok Yee Chan A.C.I.S., A.C.S. (Joint Company Sec.)
Dr. Changshou Gao Ph.D. (Sr. VP & CTO)
Ms. Vivian Zhang (Chief People Officer)
Recognition and Awards
Innovent has been recognized with numerous awards and honors including being named the most innovative biologics “Best of Show” award from the Chinapharm Prize in 2019. In 2020, Innovent Biologics was selected as one of the “100 Most Influential Chinese-Listed Companies” by Forbes China.
References
